[HTML][HTML] SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
LK Vibholm, SSF Nielsen, MH Pahus, GS Frattari… - …, 2021 - thelancet.com
Background Upon SARS-CoV-2 infection, most individuals develop neutralizing antibodies
and T-cell immunity. However, some individuals reportedly remain SARS-CoV-2 PCR …
and T-cell immunity. However, some individuals reportedly remain SARS-CoV-2 PCR …
[HTML][HTML] SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
SSF Nielsen, LK Vibholm, I Monrad, R Olesen… - …, 2021 - thelancet.com
Background The SARS-CoV-2 pandemic currently prevails worldwide. To understand the
immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new …
immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new …
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals
LK Vibholm, CV Konrad, MH Schleimann, G Frattari… - Aids, 2019 - journals.lww.com
Abstract Design: This was an exploratory, single-arm clinical trial that tested the immune
enhancement effects of 24-weeks of Toll-like receptor 9 (TLR9) agonist (MGN1703; Lefitolimod; …
enhancement effects of 24-weeks of Toll-like receptor 9 (TLR9) agonist (MGN1703; Lefitolimod; …
[HTML][HTML] High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: A randomized, phase 2, crossover trial
…, L Østergaard, LK Vibholm… - The Lancet Regional …, 2023 - thelancet.com
Background Post COVID-19 condition (PCC) is defined as symptoms lasting more than 12
weeks after developing COVID-19. Evidence of mitochondrial dysfunction has been reported …
weeks after developing COVID-19. Evidence of mitochondrial dysfunction has been reported …
Characterization of intact proviruses in blood and lymph node from HIV-infected individuals undergoing analytical treatment interruption
LK Vibholm, JCC Lorenzi, JA Pai, YZ Cohen… - Journal of …, 2019 - Am Soc Microbiol
The role of lymphoid tissue as a potential source of HIV-1 rebound following interruption of
antiretroviral therapy (ART) is uncertain. To address this issue, we compared the latent …
antiretroviral therapy (ART) is uncertain. To address this issue, we compared the latent …
Persistent severe acute respiratory syndrome coronavirus 2 infection in immunocompromised host displaying treatment induced viral evolution
…, M Tolstrup, LK Vibholm - Open forum …, 2021 - academic.oup.com
We report a coronavirus disease 2019 case with severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) persisting beyond 333 days in an immunocompromised patient with …
2 (SARS-CoV-2) persisting beyond 333 days in an immunocompromised patient with …
[HTML][HTML] TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes
MH Schleimann, ML Kobberø, LK Vibholm, K Kjær… - …, 2019 - thelancet.com
Background TLR9 agonists are being developed as immunotherapy against malignancies
and infections. TLR9 is primarily expressed in B cells and plasmacytoid dendritic cells (pDCs)…
and infections. TLR9 is primarily expressed in B cells and plasmacytoid dendritic cells (pDCs)…
[PDF][PDF] Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1
…, GS Frattari, M Rosas-Umbert, LK Vibholm… - Iscience, 2023 - cell.com
Human plasmacytoid dendritic cells (pDCs) play a central role in initiating and activating
host immune responses during infection. To understand how the transcriptome of pDCs is …
host immune responses during infection. To understand how the transcriptome of pDCs is …
Examination of autoantibodies to type I interferon in patients suffering from long COVID
…, B Schiøttz‐Christensen, LK Vibholm… - Journal of Medical …, 2023 - Wiley Online Library
Long COVID (LC) is an emerging global health concern. The underlying mechanism and
pathophysiology remain unclear. Presence of neutralizing autoantibodies against type 1 …
pathophysiology remain unclear. Presence of neutralizing autoantibodies against type 1 …
[HTML][HTML] Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
AK Hvidt, H Guo, R Andersen, SSF Lende, LK Vibholm… - BMC immunology, 2023 - Springer
Background SARS-CoV-2 remains a world-wide health issue. SARS-CoV-2-specific immunity
is induced upon both infection and vaccination. However, defining the long-term immune …
is induced upon both infection and vaccination. However, defining the long-term immune …